Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Cash & Equivalents: 2015-2024

Historic Cash & Equivalents for Intellia Therapeutics (NTLA) over the last 10 years, with Dec 2024 value amounting to $189.2 million.

  • Intellia Therapeutics' Cash & Equivalents rose 60.50% to $193.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $193.4 million, marking a year-over-year increase of 60.50%. This contributed to the annual value of $189.2 million for FY2024, which is 16.57% down from last year.
  • According to the latest figures from FY2024, Intellia Therapeutics' Cash & Equivalents is $189.2 million, which was down 16.57% from $226.7 million recorded in FY2023.
  • Intellia Therapeutics' Cash & Equivalents' 5-year high stood at $523.5 million during FY2022, with a 5-year trough of $125.5 million in FY2021.
  • In the last 3 years, Intellia Therapeutics' Cash & Equivalents had a median value of $226.7 million in 2023 and averaged $313.1 million.
  • In the last 5 years, Intellia Therapeutics' Cash & Equivalents surged by 317.18% in 2022 and then slumped by 56.69% in 2023.
  • Over the past 5 years, Intellia Therapeutics' Cash & Equivalents (Yearly) stood at $160.0 million in 2020, then decreased by 21.58% to $125.5 million in 2021, then soared by 317.18% to $523.5 million in 2022, then slumped by 56.69% to $226.7 million in 2023, then dropped by 16.57% to $189.2 million in 2024.